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Clear cell sarcoma of the kidney (CCSK) is an uncom-
mon childhood renal tumour that comprises 2–5% of 
all primary renal malignancies in children1–4. CCSK is 
observed most often in children between 2 and 4 years of 
age and shows a slight male predominance (male: female 
ratio approximately 2:1)3,5. The majority of patients pres-
ent with localized disease, and metastatic disease is iden-
tified in only 6–7% of patients at diagnosis, the most 
frequent sites being bone, lungs, and liver2,3,5.
Histologically, CCSK shows a remarkable morpho-
logical diversity (including classic, myxoid, sclerosing, 
cellular, and epithelioid patterns, among others)3. These 
variant histological patterns do not seem to be of prog-
nostic value, but they do often cause difficulties in dis-
tinguishing CCSK from other paediatric renal tumours, 
including blastemal-type nephroblastoma, mesoblastic 
nephroma, primitive neuroectodermal tumour, and 
rhabdoid tumour of the kidney, which might result in 
inappropriate or delayed treatment2. Tumour cells show 
diffuse and strong immunoreactivity for vimentin, cyc-
lin D1, low-affinity nerve growth factor receptor (NGF 
receptor; also known as NGFR), and BCL6 corepressor 
(BCoR), which can assist in diagnosing CCSK3,6–8.
Currently, the histogenesis of CCSK is uncertain. 
The genome of CCSK is rather stable, even at RNA 
and/or DNA deep-sequencing levels (mutations, copy 
number variations, and translocations are infrequent)9–12. 
A subgroup of CCSKs has been shown to harbour the 
trans location t(10;17)(q22;p13), resulting in fusion 
of YWHAE and NUTM2B or NUTM2E13. Three stud-
ies published in 2015 demonstrated that the majority 
of CCSKs have a somatic internal tandem duplication 
(ITD) in X-linked BCOR affecting the 3ʹ part of the 
exon 16 coding sequence10,12,14. These BCOR ITDs 
and t(10;17)(q22;p13) are mutually exclusive events in 
CCSK15–17. DNA methy lation profiling identified hyper-
methylation of the tumour suppressor TCF21 in CCSKs 
bearing BCOR ITDs9,17. Gene expression profiling stud-
ies reported strong and consistent upregulation of neural 
markers and members of the Sonic Hedgehog signalling 
pathway and the RACα serine/threonine-protein kinase 
(AKT) cell proliferation pathway8,9. The identified 
aberrations can be of use in the diagnosis of CCSK. To 
date, these aberrations have not been identified to be of 
prognostic or predictive value for patients with CCSK18.
After the introduction of more intensive treatment 
schedules, including anthracyclines and alkylating 
agents (commencing in 1974 in National Wilms Tumour 
Study (NWTS) protocols and in 1980 in International 
Society of Paediatric Oncology (SIOP) protocols), the 
outcome of patients diagnosed with CCSK has increased 
substantially2,3,19,20 (TABLE 1). However, a considerable 
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Abstract | The International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP–
RTSG) has developed a new protocol for the diagnosis, treatment, and follow‑up monitoring of 
childhood renal tumours — the UMBRELLA SIOP–RTSG 2016 protocol (the UMBRELLA protocol). 
This protocol has been designed to continue international collaboration in the treatment of 
childhood renal tumours and will be implemented in over 50 different countries. Clear cell 
sarcoma of the kidney, which is a rare paediatric renal tumour that most commonly occurs in 
children between 2 and 4 years of age, is specifically addressed in the UMBRELLA protocol.
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minority of patients do not have a favourable prognostic 
clinical signature (especially patients with stage IV dis-
ease, young patients, and patients with relapsed disease), 
and a plateau in survival seems to have been reached as 
current treatment protocols already contain the maxi-
mum tolerated intensity of traditional cytotoxic agents 
that can cause consequential serious toxicity2,3,21. Thus, 
the development of new (targeted) therapies is necessary 
for this group of patients.
The main mission of the SIOP–Renal Tumour Study 
Group (SIOP–RTSG) is to increase survival and reduce 
the toxicity of treatment in children diagnosed with any 
renal tumour. In this context, the SIOP–RTSG is aim-
ing to offer all paediatric patients with renal tumours 
who are enrolled in SIOP protocols standardized, high- 
quality diagnostics and treatment, independent of socio-
economic status or geographical region. To achieve these 
goals, the UMBRELLA SIOP–RTSG 2016 protocol (the 
UMBRELLA protocol), approved by the SIOP–RTSG 
and by the ethical committee in the country of the spon-
sor (Germany) (EudraCT number 2016-004180-39), is 
currently being implemented in over 50 countries22,23. 
The management of paediatric CCSK is addressed in the 
UMBRELLA protocol.
This Consensus Statement describes the rationale 
for the diagnosis, treatment, and follow-up recom-
mendations for children with CCSK included in the 
UMBRELLA protocol. Importantly, owing to the rarity 
of CCSK, no randomized trials specifically investigat-
ing CCSK have been performed, which limits the level 
of evidence available. Consequently, recommenda-
tions for CCSK included in the UMBRELLA protocol 
are based on synthesis of collated evidence (including 
observational studies and randomized trials not specific 
to CCSK) by experts in the field of CCSK to select the 
current best-available treatment.
Methods
The recommendations for CCSK have been devel-
oped by a multidisciplinary working group of selected 
SIOP–RTSG members (specialist paediatric oncologists, 
pathologists, radiologists, radiotherapists, surgeons, stat-
isticians, and other experts in the field of CCSK). These 
experts designed the consensus regarding diagnostics, 
best-available treatment, and follow-up methods based 
on an extensive review of the literature on CCSK5 and 
an analysis of treatment and outcomes of patients with 
CCSK treated according to the most recent SIOP 93–01 
and SIOP 2001 protocols2.
Background to the rationale
In general, the treatment of paediatric patients with 
renal tumours follows two contrasting recommen-
dations internationally, which have been different from 
inception (TABLE 1). The European SIOP recommenda-
tions advocate preoperative chemotherapy consisting of 
two drugs (vincristine and actinomycin) in instances of 
localized disease and three drugs (vincristine, actino-
mycin, and doxorubicin) in instances of metastatic 
disease for children between 6 months and 16 years 
of age. The North American National Wilms Tumor 
Study Group (NWTS) and its successor, the Children’s 
Oncology Group (COG), recommend immediate sur-
gery for children of all ages when it can be performed 
safely. Both policies result in similar survival (TABLE 1). 
Preoperative chemotherapy given according to the SIOP 
policy has been shown to result in downstaging of pae-
diatric renal tumours, leading to a reduction in ther-
apy. The two regimens (SIOP and NWTS–COG) were 
compared in the UK Wilms Tumour trial 3 (UKW3), in 
which patients were randomly assigned either to imme-
diate nephrectomy or to preoperative chemo therapy; 
20% of renal tumour survivors were spared the late 
effects of doxorubicin and radiotherapy by treating them 
with preoperative chemotherapy24. In addition, the SIOP 
policy enables assessment of histological response to 
treatment24. Upfront resection according to the NWTS 
and COG protocol enables immediate, accurate assess-
ment of the histological diagnosis and tumour extent as 
well as the harvesting of pretherapy tumour tissue, which 
is useful for research purposes. Consequently, most 
patients with CCSK treated according to SIOP protocols 
are diagnosed after preoperative chemotherapy, whereas 
patients treated according to NWTS and COG proto-
cols are diagnosed before chemotherapeutic treatment. 
Historically, CCSK has been treated using chemotherapy 
regimens similar to those used for the treatment of high-
risk Wilms tumour as the rarity of CCSK has limited 
studies or trials specifically tailored to CCSK.
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Table 1 | Previous and current treatment protocols including clear cell sarcoma of the kidney
Study (period) 
and number 
of included 
patients with 
CCSK
Study design (quality 
of evidencea) and study 
limitations
Preoperative 
treatment
Postoperative treatment Outcome
Chemotherapy Radiotherapy EFS OS Relapse 
rate
SIOP studies
SIOP 1 
(REFS 26,74) 
(1971–1974) 
NAb
• RCT (low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• Outcome of patients with 
CCSK has been described 
only for combined studies 
(not for each study 
separately)
• Patients with stage IV disease 
were excluded from the trial 
(all excluded patients were 
included in prospective 
registration studies)
Randomization: 
primary 
surgery versus 
radiotherapy 
(20 Gy)
Randomization: 
one course of 
AMD versus 
seven courses of 
AMD
Randomization: 
postoperative 
only 
(stage I: 20 Gy, 
stage II–III: 
30 Gy) versus 
preoperative 
(20 Gy) and 
postoperative 
(stage II–III: 
15 Gy)
30% 
(5‑year)b
43%  
(5‑year)b
NA
SIOP 2 
(REFS 25,26,75)  
(1974–1976) 
NAb
• Observational (very low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• Outcome of patients with 
CCSK has been described 
only for combined studies 
(not for each study 
separately)
• Patients with stage IV 
disease were excluded 
from the trial (all excluded 
patients were included in 
prospective registration 
studies)
Radiotherapy 
(20 Gy)
Stage I–IV: AV 
(for 9 months or 
15 months)
Stage II–III: 
15 Gy
30% 
(5‑year)b
43%  
(5‑year)b
NA
SIOP 5 
(REFS 25,26) 
(1977–1979) 
NAb
• RCT (low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• Outcome of patients with 
CCSK has been described 
only for combined studies 
(not for each study 
separately)
• Patients with stage IV 
disease were excluded 
from the trial (all excluded 
patients were included in 
prospective registration 
studies)
Randomization: 
radiotherapy 
(20 Gy) + AMD 
versus AVc
Stage I–IV: AV Stage II–III: 
15 Gy (in 
instances of 
preoperative 
radiotherapy) 
or 30 Gy (no 
preoperative 
radiotherapy)
30% 
(5‑year)b
43%  
(5‑year)b
NA
SIOP 6 (REF. 27) 
(1980–1987) 
n = 15
• RCT (no evidenced)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• Patients with stage IV 
disease were excluded 
from the trial (all excluded 
patients were included in 
prospective registration 
studies)
• Exclusion of unfavour‑
able‑histology tumours 
(including CCSK; 
some CCSKs were 
included owing to initial 
misdiagnosis)
AV • Stage I 
randomization: 
AV for 17 weeks 
versus AV for 
38 weeks
• Stage IIN0: AV 
for 38 weeks
• Stage IIN1/III 
randomization: 
AV versus AVD
• Stage IIN0 
randomization: 
radiotherapy 
(20 Gy) 
versus no 
radiotherapy
• Stage IIN1 or 
III: 30 Gy
NA NA NA
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SIOP studies (cont.)
SIOP 9 (REF. 28) 
(1987–1991) 
n = 16
• RCT (low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• Patients with stage IV disease 
were excluded from the trial 
(all excluded patients were 
included in prospective 
registration studies)
Randomization: 
AV 4 weeks 
versus AV 
8 weeksc
Stage I–IV: AVEI Stage II–III: 
30 Gy
75%  
(2‑year)
88%  
(5‑year)
NA
SIOP 93–01 
(REF. 2) 
(1993–1999) 
n = 100
• Observational (low)
• Outcome of patients with 
CCSK has been described only 
for combined studies (not for 
each study separately)
• Stage I–III: AV
• Stage IV: AVD
Stage I–IV: ECID Stage II–III: 
25–30 Gy
78%  
(5‑year)e
86%  
(5‑year)e
15%
SIOP 2001 (REF. 2) 
(2001–2016) 
n = 91
• Observational (low)
• Outcome of patients with 
CCSK has been described only 
for combined studies (not for 
each study separately)
• Stage I–III: AV
• Stage IV: AVD
• Stage I: AVD
• Stage II–IV: 
ECCD
Stage II–III: 
25.2 Gy
78%  
(5‑year)e
86%  
(5‑year)e
15%
UK SIOP 2001 
(2001–2011) 
NA
• Observational (no evidenced)
• Number of included patients 
with CCSK unknown
AVD • Stage I–III: AVD
• Stage IV: ECCD
Stage II–III: 
25.2 Gy (before 
2009, only 
radiotherapy 
for stage III)
NA NA NA
UMBRELLA (2017– 
ongoing) NA
• Observational (NA)
• NA
• Stage I–III: AV
• Stage IV: AVD
Stage I–IV: ECICD Stage II–III: 
10.8 Gy
NA NA NA
NWTS and COG studies
NWTS 1 
(REFS 19,76) 
(1969–1973) 
n = 23
• RCT (low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• Outcome of patients with 
CCSK has been described 
only for combined studies (not 
for each study separately)
• Stage I–III: 
primary 
surgery
• Stage IV 
randomization: 
primary surgery 
versus VCR
• Stage I: AMD
• Stage II–III 
randomization 
AMD versus 
VCR versus AV
• Stage IV: AV
• Stage I 
randomization: 
radiotherapy 
(18–40 Gy) 
versus no 
radiotherapy
• Stage II–IV: 
18–40 Gy
• AV (n = 8): 
25% (6‑year)
• AVD (n = 58): 
64% (6‑year)
• AVDC 
(n = 30): 
58% (6‑year)f
• AV (n = 8): 
25% (6‑year)
• AVD (n = 58): 
72% (6‑year)
• AVDC 
(n = 30): 
61% (6‑year)f
NA
NWTS 2 
(REFS 19,77) 
(1974–1978) 
n = 23
• RCT (low)
• Small CCSK cohort size
• CCSKs were included in a study 
focused mainly on Wilms tumour
• Outcome of patients with 
CCSK has been described 
only for combined studies (not 
for each study separately)
Primary surgery • Stage I 
randomization: 
AV for 6 months 
versus AV for 
15 months
• Stage II–IV 
randomization: 
AV versus AVD
Stage II–IV: 
18–40 Gy
• AV (n = 8): 
25% (6‑year)
• AVD (n = 58): 
64% (6‑year)
• AVDC 
(n = 30): 
58% (6‑year)f
• AV (n = 8): 
25% (6‑year)
• AVD (n = 58): 
72% (6‑year)
• AVDC 
(n = 30): 
61% (6‑year)f
NA
NWTS 3 
(REFS 19,78) 
(1979–1985) 
n = 73
• RCT (moderate)
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
Primary surgery Stage I–IV 
randomization: 
AVD versus AVDC
Stage I–IV: 
10.8–40 Gy
• AV (n = 8): 
25% (6‑year)
• AVD (n = 58): 
64% (6‑year)
• AVDC 
(n = 30): 
58% (6‑year)
• NWTS 3: 
60% (8‑year)f
• AV (n = 8): 
25% (6‑year)
• AVD (n = 58): 
72% (6‑year)
• AVDC 
(n = 30): 
61% (6‑year)
• NWTS 3: 
67% (8‑year)f
39%
NWTS 4 (REF. 29) 
(1986–1994) 
n = 86
• RCT (moderate)
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
Primary surgery Stage I–IV 
randomization: 
AVD 6 months 
versus 16 months
Stage I–IV: 
10.8 Gy
• AVD for 
6 months: 
61% (8‑year)
• AVD for 
16 months: 
88% (8‑year)
• Overall: 72% 
(8‑year)
• AVD for 
6 months: 
86% (8‑year)
• AVD for 
16 months: 
88% (8‑year)
• Overall: 83% 
(8‑year)
27%
Table 1 (cont.) | Previous and current treatment protocols including clear cell sarcoma of the kidney
Study (period) 
and number 
of included 
patients with 
CCSK
Study design (quality 
of evidencea) and study 
limitations
Preoperative 
treatment
Postoperative treatment Outcome
Chemotherapy Radiotherapy EFS OS Relapse 
rate
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SIOP trials
The first SIOP trials (SIOP 1, SIOP 2, and SIOP 5, 
conducted between 1971 and 1979), in which CCSKs 
were treated in the same way as Wilms tumours, used 
preoperative or postoperative radiotherapy and/or 
chemotherapy consisting of actinomycin alone or in 
combination with vincristine. The results of these trials 
showed a 5-year event-free survival (EFS) of 30% and 
a 5-year overall survival (OS) of 43% for patients with 
CCSK (n = 33, all three trials; TABLE 1)25,26. The results 
NWTS and COG studies (cont)
NWTS 5 (REF. 20) 
(1995–2002) 
n = 110
• Observational (low)
• NA
Primary surgery Stage I–IV: ECVD Stage I–IV: 
10.8 Gy
79%  
(5‑year)
89% (5‑year) 19%
AREN0321 
(2006–2013) 
NA
• Observational (NA)
• NA
Primary surgery Stage I–III: ECVD
Stage IV: ECVDC
Stage II–IV: 
10.8 Gy
NA NA NA
Other studies
UKW1 (REF. 79)  
(1980–1986) 
n = 14
• Observational (very low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• EFS data not available for 
patients with CCSK
Primary surgery Stage I–IV: AVDC Stage II–IV: 
30 Gyg
NA 79% (6‑year) NA
UKW2 (REF. 31) 
(1986–1991) 
n = 18
• Observational (very low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
Primary surgery Stage I–IV: AVD Stage III–IV 
(stage IV: 
treatment with 
radiotherapy 
only in 
instances of 
local stage III 
disease): 30 Gy
82% (4‑year) 88% (4‑year) NA
UKW3 (REF. 24) 
(1991–2001) 
n = 8
• RCT (no evidenced)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
• Patients with stage IV disease 
were excluded from the trial 
(all excluded patients were 
included in prospective 
registration studies)
Randomization: 
AV versus 
primary surgery
Stage I–III: AVD Stage III: 30 Gy NA NA NA
AIEOP TW‑2003 
(REF. 33)  
(2003–2017) 
n = 14
• Observational (very low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
Primary surgery Stage I–IV: ECID Stage I–III: 
19.8 Gy
84% (5‑year) 91% (5‑year) 14%
JWiTs‑1 (REF. 34) 
(1996–2005) 
n = 16
• Observational (very low)
• Small CCSK cohort size
• CCSKs were included in a 
study focused mainly on 
Wilms tumour
Primary surgery Stage I–IV: ECVD Stage I–IV: 
10.8 Gy
73% (5‑year) 75% (5‑year) NA
AMD, actinomycin; AV, actinomycin and vincristine; AVD, actinomycin, vincristine, and doxorubicin; AVDC, actinomycin, vincristine, doxorubicin, and cyclophosphamide; AVEI, 
actinomycin, vincristine, epirubicin, and ifosfamide; CCSK, clear cell sarcoma of the kidney; COG, Children’s Oncology Group; ECCD, etoposide, carboplatin, cyclophosphamide, 
and doxorubicin; ECICD, etoposide, carboplatin, ifosfamide, cyclophosphamide, and doxorubicin; ECID, etoposide, carboplatin, ifosfamide, and doxorubicin; ECVD, etoposide, 
cyclophosphamide, vincristine, and doxorubicin; ECVDC, etoposide, cyclophosphamide, vincristine, doxorubicin, and carboplatin; EFS, event‑free survival; JWiTs, Japan Wilms 
Tumor Study group; NA, not applicable; NWTS, National Wilms Tumor Study; OS, overall survival; RCT, randomized controlled trial; SIOP, International Society of Paediatric 
Oncology; VCR, vincristine. aStudies were graded according to the GRADE system of the GRADE working group80. bResults of patients with CCSK treated in SIOP 1–5 studies were 
only described together, not separately for the SIOP 1, SIOP 2, and SIOP 5 studies. In total, 33 patients with CCSK were included in SIOP 1–5 studies.cSIOP 5 and SIOP 9 did not 
describe how randomization affected patients with CCSK; only outcomes of the whole group of patients with CCSK have been reported. dNo evidence available because  
no outcome data have been reported for patients with CCSK. eResults of patients with CCSK treated in SIOP 93‑01 and SIOP 2001 studies were only described together, not 
separately for both studies. fResults of patients with CCSK treated in NWTS 1−3 studies were described together, only results of patients with CCSK treated in NWTS 3 have also 
been described separately. g In the case of residual disease after second‑look or delayed surgery.
Table 1 (cont.) | Previous and current treatment protocols including clear cell sarcoma of the kidney
Study (period) 
and number 
of included 
patients with 
CCSK
Study design (quality 
of evidencea) and study 
limitations
Preoperative 
treatment
Postoperative treatment Outcome
Chemotherapy Radiotherapy EFS OS Relapse 
rate
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of the first two SIOP trials demonstrated the benefit of 
preoperative radiotherapy (significantly fewer tumour 
ruptures, P < 0.001). The SIOP 5 trial showed that pre-
operative chemotherapy was equivalent to preoperative 
radiotherapy in terms of prevention of tumour rupture. 
Thus, all subsequent SIOP treatment regimens contained 
recommendations for preoperative chemotherapy, at 
least in patients older than 6 months of age. Owing to 
the toxic effect of irradiation in small children, radio-
therapy was used only as postoperative therapy in sub-
sequent regimens. The sixth SIOP study (conducted 
between 1980 and 1987), in which patients were treated 
with preoperative actinomycin and vincristine and post-
operative actinomycin and vincristine with or without 
additional doxorubicin and/or radiotherapy, included 
only patients with a favourable-histology Wilms tumour 
(TABLE 1). Some 15 patients with CCSK were included 
in this study after initial misdiagnosis, but outcomes of 
these patients were not reported separately27. The SIOP 
9 study (conducted between 1987 and 1991), including 
patients with nonmetastatic renal tumours, showed 
a substantial increase in EFS and OS of patients with 
CCSK after the addition of an anthracycline (epi rubicin 
or doxorubicin), an alkylating agent (ifosfamide), and 
radiotherapy to a dose of 30 Gy (in instances of local 
stage II and III disease) to the treatment protocol, result-
ing in a 2-year EFS of 75% and 5-year OS of 88% (n = 16; 
TABLE 1)28. Patients with CCSK subsequently registered 
in SIOP 93–01 (conducted between 1993 and 2001) 
received adjuvant treatment consisting of etoposide, 
carboplatin, ifosfamide, and epirubicin or doxorubicin 
(doxorubicin in German, Austrian, and Swiss centres) 
(n = 100; TABLE 1). Postoperative therapy was reduced to 
three drugs (actinomycin, vincristine, and doxorubicin) 
in patients with high-risk stage I tumours (including 
CCSK) registered in SIOP 2001 (conducted between 
2001 and 2016) to decrease toxicity while maintaining 
doxorubicin as part of the treatment (n = 27; TABLE 1). 
Etoposide, carboplatin, and doxorubicin, with cyclo-
phosphamide replacing ifosfamide (because of the 
potential risk of tubular damage to the remaining kid-
ney), continued to be used in patients with stage II–IV 
disease in SIOP 2001 (n = 64; TABLE 1)2. SIOP 93–01 and 
SIOP 2001 protocols included additional irradiation 
to the flank (25–30 Gy in SIOP 93–01 and 25.2 Gy in 
SIOP 2001) in instances of local stage II and stage III 
disease. In terms of assessing responsiveness of CCSK 
to pre operative chemotherapy, in the SIOP 93–01 and 
SIOP 2001 trials, a partial response was observed in 
21% of patients, a minor response in 15%, stable dis-
ease in 31%, and progressive disease in 33% (according 
to RECIST criteria)2. The 5-year EFS and OS of all 191 
patients with CCSK registered in SIOP 93–01 and SIOP 
2001 protocols were 78% and 86%, respectively2. Stage 
IV disease (P = 0.0315) and age <12 months (P = 0.0004) 
were significant adverse prognostic factors for EFS2. For 
patients treated with alkylating agents (ifosfamide or 
cyclophosphamide, n = 146), 5-year EFS and OS were 
83% and 88%, respectively, compared with 67% and 
78%, respectively, for patients treated without alky-
lating agents (n = 28)2. Notably, the 5-year EFS and OS 
of patients with stage I disease treated according to SIOP 
93–01 (four drugs, including alkylating agent, n = 53) 
were 83% and 90%, respectively, compared with 72% and 
80%, respectively, for patients with stage I disease treated 
according to the SIOP 2001 protocol (three drugs, no 
alkylating agent, n = 27)2. The data from this study sug-
gest that postoperative treatment including alkylating 
agents might improve EFS and OS for patients with 
CCSK, although the study was an observational cohort 
study and not a randomized controlled trial. This differ-
ence in treatment protocols could explain why patients 
with stage I disease treated according to the SIOP 2001 
protocol (without alkylating agents) had inferior survival 
to patients with stage I disease treated according to the 
SIOP 93–01 protocol (including alkylating agents).
NWTS trials
Results from the first three NWTS trials (conducted 
between 1969 and 1986) showed that the addition of 
doxorubicin to the combination of vincristine and 
actinomycin improved the 6-year EFS of patients with 
CCSK from 25% to 64% (n = 23; TABLE 1)19. Argani 
et al.3 confirmed the beneficial effect of doxorubicin in 
a retro spective review of 182 patients with CCSK treated 
according to the regimens in NWTS 1–4 (REF. 3). After 
these first NWTS trials, doxorubicin remained part 
of the treatment of patients with CCSK registered in 
NWTS protocols. The addition of cyclophosphamide 
did not further improve the 6-year EFS in NWTS 3; 
however, cyclophosphamide was administered at a 
fairly low dose and intensity (ten courses of 10 mg per 
kg daily for 3 days), which might have been too low 
to be effective (n = 73; TABLE 1)19. Results of the NWTS 
1–3 trials indicated that the frequency of flank relapses 
did not increase with the use of reduced radio therapy 
doses to the lower flank; according to these data, a 
radiotherapy dose of 10.8 Gy has been used in all sub-
sequent NWTS protocols19. Based on the results of 
NWTS 3, cyclophosphamide was not routinely used in 
the subsequent NWTS 4 regimen19,29. Results of NWTS 
4 (conducted between 1986 and 1995) indicated that 
a 16-month course of vincristine, actinomycin, and 
doxorubicin results in superior 8-year EFS compared 
with a 6-month course (EFS 88% versus 61%), but 
long-term survival after both courses was equal (8-year 
OS 88% versus 86%, n = 86; TABLE 1)29. NWTS 5 (con-
ducted from 1995 to 2002) was designed to improve 
the EFS and OS for patients with CCSK by incorpo-
rating cyclo phosphamide (at a higher dose than given 
on NWTS 3) and etoposide in combination with vin-
cristine and doxorubicin (duration of treatment was 
6 months) and postoperative radiotherapy (n = 110; 
TABLE 1)20. Overall, 5-year EFS and OS were 79% and 
89%, respectively, similar to outcomes of the NWTS 4 
trial20. In total, 21 of 110 (19%) patients in the NWTS 5 
trial developed a relapse, fewer than in previous studies. 
Only one of these recurrences occurred in the tumour 
bed and two relapses occurred elsewhere in the abdo-
men, indicating that local control was achieved in the 
majority of patients after radiotherapeutic treatment 
with a dose of only 10.8 Gy (J.S. Dome, former chair 
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COG renal tumour study group, personal communi-
cation). Retrospective analysis of patients with stage I 
CCSK (according to NWTS 5 staging criteria)30 enrolled 
in NWTS 1–5 trials (n = 53) showed 100% EFS and OS 
at the last follow-up examination (median follow-up 
duration 17 years, range 2–36 years) despite the use of 
varying radio therapy doses and chemotherapy regi-
mens30. Treatment of patients with CCSK according to 
the AREN0321 COG protocol (conducted between 2006 
and 2013) consisted of surgery of resectable tumours 
followed by adjuvant vincristine, cyclophosphamide, 
doxorubicin, and etoposide for patients with stage 
I–III disease, whereas stage IV patients were treated 
using an intensified regimen with additional carbo-
platin. Patients with local stage II–III disease received 
postoperative radiotherapy (10.8 Gy; TABLE 1). Based 
on the excellent survival of patients with stage I CCSK 
included in NWTS 1–5 protocols, the renal tumour com-
mittee of the COG decided to prospectively study the 
outcome of patients with stage I disease after treatment 
with surgery and chemotherapy alone, without additional 
radiotherapy (only if adequate surgical staging with 
lymph node sampling and central pathology review has 
been performed)30. The AREN0321 study has been closed 
since November 2013 and will be evaluated shortly.
Other trials
Treatment of patients with CCSK according to the 
UKW1 trial (conducted between 1980 and 1986) con-
sisted of primary surgery and postoperative treatment 
with vincristine, actinomycin, doxorubicin, and cyclo-
phosphamide. In addition, radiotherapy (30 Gy) was 
applied in instances of residual disease after second-look 
surgery in patients with stage II–IV disease (TABLE 1). The 
6-year OS of patients with CCSK in this trial (n = 14) 
was 79% (EFS was not separately reported for CCSK 
patients). UKW2 (conducted from 1986 to 1991) was 
designed to improve the outcome of patients with 
tumours of unfavourable histology, including CCSK 
(n = 18), by intensification of chemotherapy scheduling 
of vincristine, actinomycin, and doxorubicin and addi-
tion of radiotherapy in patients with local stage III dis-
ease (30 Gy TABLE 1)31. In this trial, 4-year EFS and OS of 
CCSK patients were 82% and 88%, respectively. Patients 
with nonmetastatic CCSK (n = 8) treated according 
to the UKW3 protocol (conducted between 1991 and 
2001) were randomized among all patients with kidney 
tumours to either immediate surgery or preoperative 
chemotherapy (vincristine and actinomycin). Adjuvant 
treatment was identical to that used in the UKW2 study 
(TABLE 1). EFS and OS were not separately reported for 
patients with CCSK (TABLE 1)24. After UKW3, the UK 
Children’s Cancer Study Group joined the SIOP 2001 
trial but continued to recommend vincristine, actino-
mycin, and doxorubicin for localized CCSK (TABLE 1). 
Combined analysis of patients with CCSK treated 
according to regimens in the UKW2, UKW3, and UK 
SIOP 2001 trials (n = 55) revealed a high local relapse 
rate (65%) in patients with stage II disease not treated 
with radiotherapy32 (K.P.-J., unpublished preliminary 
UK CCSK data observation).
In the TW-2003 protocol of the Associazione Italiana 
di Ematologia e Oncologia Pediatrica (AIEOP; con-
ducted between 2003 and 2017), patients with CCSK 
were treated according to the regimen for high-risk 
Wilms tumours, consisting of immediate surgery, 
unless the tumour is considered inoperable, followed 
by treatment with etoposide, ifosfamide, carboplatin, 
and doxorubicin (TABLE 1). Radiotherapy (19.8 Gy) was 
recommended for stage I–III disease. This regimen has 
resulted in a 5-year EFS of 84% and 5-year OS of 91% 
(n = 14)33.
The first Japan Wilms Tumour Study Group trial 
(JWiTs-1; conducted between 1996 and 2005) used sim-
ilar treatment regimens for CCSK patients to the NWTS 
5 trial (vincristine, doxorubicin, cyclophosphamide, 
etoposide, and postoperative radiotherapy to a dose of 
10.8 Gy for all patients, regardless of stage; TABLE 1). In 
this trial, 5-year EFS and OS were 73% and 75%, respec-
tively (n = 15)34.
The latter trials supported the evidence from SIOP 
and NWTS–COG studies that have informed the 
decisions made in the UMBRELLA protocol.
Recommendations in the UMBRELLA protocol
Diagnostics
All patients with renal tumours enrolled in the 
UMBRELLA protocol will be diagnosed in a standard-
ized way, which simplifies the procedure for clinicians 
and enables the interpretation of results of a large cohort 
of patients in a uniform manner. An overview of stand-
ard diagnostic investigations during the preoperative 
and postoperative phase is provided in the UMBRELLA 
protocol (available at www.siop-rtsg.eu).
Pathology. The morphology of CCSK shows a remark-
able diversity, which can result in considerable diagnos-
tic difficulty2,3. In the SIOP 93–01 and SIOP 2001 studies, 
27% of CCSKs were initially diagnosed as other renal 
tumours by local pathologists2. This misidentification 
stresses the importance of a rapid and central pathology 
review of all suspected instances of CCSK by national 
pathology panels, which work in coordination with 
the SIOP pathology panel. This procedure has become 
standard for all patients with renal tumours registered in 
SIOP studies since SIOP 2001. Central pathology review 
should be completed within 2 weeks after nephrectomy, 
which will enable communication of the results of the 
review back to the institutional team before decisions 
on postoperative therapy are implemented. Similarly, 
the COG includes central pathology review in their 
diagnostic protocol (since the first NWTS trials)35.
Radiology. The only reported retrospective study that 
has investigated the radiolographical characteristics of 
CCSK concluded that no features can reliably distin-
guish CCSK from other paediatric renal tumours36,37. 
In general, radiological diagnostic work-up of patients 
diagnosed with CCSK follows the standard work-up for 
paediatric renal tumours. Once the diagnosis of CCSK 
is made, brain MRI is advised as a complementary 
baseline investigation, as observational studies of the 
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AIEOP, SIOP, and COG renal tumour study groups have 
identified the brain to be a preferential site for CCSK 
meta stasis, especially in the relapse setting (approx-
imately 40% of relapses are located in the brain)20,21. 
Furthermore, whole-body FDG–PET (sensitiv-
ity ± 90%), whole-body MRI (sensitivity ± 82%), or 99mTc 
bone scan (sensitivity ± 71%) is recommended as bone 
is one of the most common metastatic sites at diagnosis 
(in SIOP 93–01 and SIOP 2001, 69% of metastases at 
diagnosis occurred in the bone, and in NWTS 5 22% 
of metastasis at diagnosis occurred in the bone)2,20,38.
Genetic counselling. No CCSK-related syndromes have 
been reported; thus, counselling by a clinical geneticist 
is not routinely recommended in individuals without a 
family history of multiple cancers at a young age.
Treatment recommendations
The UMBRELLA protocol aims to include chemother-
apy regimens that have been shown to be of value for 
patients with CCSK in order to maintain excellent sur-
vival for patients with localized CCSK and to further 
improve survival if possible. Moreover, the UMBRELLA 
protocol takes into account that survival is already rea-
sonable for some groups of patients, but at the cost of 
fairly intensive treatment. Thus, this protocol aims to 
de-intensify standard therapy selectively to minimize 
serious short-term and long-term toxicity if feasible.
Many national and international randomized trials 
and observational studies on renal tumours in which 
patients with CCSK have been included provide only a 
very low to moderate level of evidence to direct further 
improvement using conventional chemotherapy and 
radiotherapy (TABLE 1). Hence, the recommendations 
for treatment of CCSK in the UMBRELLA protocol are 
based on expert opinion of a synthesis of this collated 
evidence to select treatments associated with the best 
reported outcomes to date.
General treatment recommendations. The UMBRELLA 
protocol recommends continuing to treat all patients 
with renal tumours (including CCSK) between 6 months 
and 16 years of age with preoperative chemotherapy 
(vincristine and actinomycin for localized disease and 
vincristine, actinomycin, and doxorubicin for metastatic 
disease) based on the demonstrated downstaging effect 
of preoperative chemotherapy, resulting in treatment 
reduction24 (TABLE 2).
The addition of anthracyclines (doxorubicin) to 
the postoperative treatment regimen of patients diag-
nosed with CCSK has been shown to result in a sig-
nificant improvement in outcome (relative risk 0.22 
(P < 0.001))3. Thus, doxorubicin will continue to be 
part of the treatment of all patients diagnosed with 
CCSK in the UMBRELLA protocol. Dosing of doxo-
rubicin in the UMBRELLA protocol is mainly based 
on the recommendations described for CCSK in the 
previous SIOP 2001 protocol. The only adjustment is 
a reduction of the cumulative dose from 300 mg/m2 to 
250 mg/m2 for CCSK patients with stage II or stage III 
disease with the aim of decreasing cardiotoxicity and 
toxicity in general, as COG studies have shown that 
reduced anthracycline doses seem to be sufficient in 
these patients (the maximum total cumulative doses 
of doxorubicin included in the UMBRELLA proto-
col for CCSK are 250 mg/m2 for localized disease and 
300 mg/m2 for metastatic disease) (TABLE 2).
Moreover, the benefit of including alkylating agents in 
the treatment of patients diagnosed with CCSK is incor-
porated in the UMBRELLA protocol2, to reduce the risk 
of serious renal toxicity caused by ifosfamide39–42 as well 
as the occurrence of second tumours or fertility problems 
caused by cyclophosphamide43–45. Combining the alkylat-
ing agents ifosfamide and cyclophosphamide in an alter-
nating setting to reduce the total cumulative dose of either 
drug was decided by consensus (TABLE 2). Irrespective of 
disease stage, patients will be treated with postoperative 
alternating ifosfamide and cyclophosphamide in com-
bination with etoposide, carboplatin, and doxorubicin, 
including patients with stage I disease, on the basis of the 
superior survival of patients with stage I disease treated 
according to the SIOP 93–01 protocol (TABLE 2)2.
Observational cohort studies have shown that the 
pattern of relapses is changing, as the most common site 
Table 2 | Overview of therapy according to stage
Stage Preoperative 
chemotherapya
Postoperative chemotherapy Abdominal radiotherapy
I AV Etoposide, carboplatin, ifosfamide alternating with cyclophosphamide, and 
doxorubicin
No
II AV Etoposide, carboplatin, ifosfamide alternating with cyclophosphamide, and 
doxorubicin
Yesb
III AV Etoposide, carboplatin, ifosfamide alternating with cyclophosphamide, and 
doxorubicin
Yesb
IV AVD Etoposide, carboplatin, ifosfamide alternating with cyclophosphamide, and 
doxorubicin or vincristinec
According to local stage and 
radiotherapy of metastatic sitesb,d
AV, actinomycin and vincristine; AVD, actinomycin, vincristine, and doxorubicin; NA, not applicable. aIf clear cell sarcoma of the kidney has been confirmed by 
biopsy before the start of preoperative chemotherapy, starting treatment with five drugs (postoperative chemotherapy schedule) is advised instead of standard 
preoperative chemotherapy; evaluate the possibility of surgery after two cycles of chemotherapy (performing surgery within 6 weeks after the start of 
chemotherapy is recommended). bFor detailed radiotherapy recommendations, see the ‘Radiotherapeutic Guidelines’ chapter of the UMBRELLA protocol. cReplace 
doxorubicin with vincristine after reaching a total cumulative dose of 300 mg/m2. dAbdominal radiotherapy in instances of local stage II–III disease. Radiotherapy to 
metastases is indicated regardless of response to preoperative chemotherapy or surgical treatment (radiotherapy doses for metastases are described in the 
UMBRELLA protocol).
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of CCSK recurrence is now brain rather than bone20,21. 
This observation suggests that the brain might be a 
sanctuary that protects tumour cells from the intensive 
chemotherapy that patients currently receive. For this 
reason, agents that penetrate the central nervous system, 
such as ifosfamide and carboplatin, will continue to be 
included in the treatment regimen46–49 (TABLE 2).
Radiotherapy seems to be beneficial in the treatment 
of selected patients diagnosed with CCSK3,5,32. Children 
undergoing abdominal radiotherapy are at an increased 
risk of developing orthopaedic, renal, metabolic, hepatic, 
gonadal, and vascular problems in addition to an increased 
risk of treatment-induced neoplasms50–52. The new 
UMBRELLA protocol has implemented the local radio-
therapy dose of 10.8 Gy used by the COG following the 
efficacy of the low-dose radiotherapy (10.8 Gy) used in the 
NWTS 4, NWTS 5, and AREN0321 trials20 (TABLES 1,2). 
A stopping rule has been defined for early detection of 
unexpectedly high local relapse rates. Quantitative limits 
set for the stopping rule for patients with CCSK treated 
with the new radiotherapy dose, designed by the SIOP–
RTSG statistician (H.v.T.), are described in detail in the 
UMBRELLA protocol (available at www.siop-rtsg.eu). In 
line with previous SIOP 93–01 and SIOP 2001 protocols 
and the current COG protocol, patients with local stage 
II–III CCSK should receive postoperative abdominal 
radio therapy; treatment with radiotherapy is not indicated 
for patients with stage I disease (TABLES 1,2).
Treatment recommendations for metastatic disease. 
For patients with haematogenous or lymph node meta-
stases outside the abdominal–pelvic region (stage IV 
disease) still present after treatment with preoperative 
chemotherapy (three drugs), metastasectomy is advised 
whenever surgery can be performed without mutilation 
or loss of vital organs. Regardless of response to preoper-
ative chemotherapy or surgical treatment, radiotherapy 
to metastatic sites is indicated in patients with stage IV 
CCSK (TABLE 2). Based on extrapolating the results of pro-
spective and review studies on adults and expert opinion, 
the use of highly conformal techniques can be considered 
in patients with metastatic CCSK, especially in instances 
of solitary metastasis or oligometastases, depending on 
the anatomical site53,54. Postoperative treatment is consist-
ent with previous SIOP 93–01 and SIOP 2001 protocols, 
with the specific outlined differences, and consists of the 
five chemotherapeutic agents used for localized disease 
and abdominal radiotherapy (dose 10.8 Gy as in COG) 
for local stage II or III disease (TABLES 1,2). To limit car-
diotoxicity and toxicity in general, doxorubicin will be 
replaced by vincristine after exceeding the maximum 
cumulative dose of 300 mg/m2, which is similar to what 
was recommended in the previous SIOP 2001 protocol20. 
The benefit of high-dose chemotherapy for metastatic 
CCSK patients has not been reported to date.
Treatment recommendations for relapsed disease. 
A descriptive cohort study of SIOP–RTSG and 
AIEOP trials including 37 patients in total, the larg-
est cohort of patients with CCSK who experienced 
relapse described to date, reported that outcome after 
relapse is poor (5-year EFS 18%, 5-year OS 26%)21. 
Results of the analysis of the SIOP–RTSG and SIOP–
AIEOP studies (n = 37) and a descriptive study by 
Radulescu et al.53 (n = 8) indicate that intensive treat-
ment, including chemotherapy as well as achieving 
local control by surgery and/or radiotherapy, seems to 
increase survival of patients with relapsed CCSK21,55. 
However, statistical evidence is lacking, owing to 
the small number of patients included in these stud-
ies. Furthermore, treatment with high-dose chemo-
therapy (extremely high, potentially toxic doses of 
chemo therapy) followed by autologous stem cell trans-
plantation (HD-ASCT) to consolidate the second com-
plete remission seems to be of value21,55. In total, the 
outcomes of 24 patients with CCSK who experienced 
relapse and received HD-ASCT have been reported in 
the literature, of whom 50% were alive without dis-
ease after a median follow-up duration of 52 months, 
whereas the average 5-year OS of patients with relapsed 
CCSK is about 26%21,55–58. Importantly, this HD-ASCT 
treatment was mostly given to a selected group of 
patients with relapsed disease who already achieved 
second complete remission; thus, the positive effect of 
HD-ASCT might (in part) be attributable to this selec-
tion of patients. Furthermore, the risk of HD-ASCT-
related toxicity needs to be weighed against the risk 
of disease-related mortality. Providing a recommen-
dation regarding the best high-dose chemotherapy 
schedule for relapsed patients with CCSK is not pos-
sible owing to the small number of patients treated in 
this manner and the many drug combinations used. 
To enable evaluation of treatment, the high-dose 
treatment schedule in the UMBRELLA protocol has 
been defined as melphalan (200 mg/m2 total dose over 
1 hour) by consensus, which is similar to the high-dose 
regimen recommended for relapsed Wilms tumour in 
the UMBRELLA protocol. Melphalan was the most 
commonly used high-dose agent in the SIOP–AIEOP 
relapsed CCSK study; eight patients were treated with 
high-dose melphalan, of whom four patients were alive 
without disease and four patients died of disease after a 
median follow-up time of 29 months21. Moreover, high-
dose melphalan has previously been successfully used 
in the treatment of other recurrent paediatric solid 
tumours, such as neuroblastoma59,60.
For other sarcomas and solid tumours in children (for 
example, Ewing sarcoma and Wilms tumour), next-gen-
eration chemotherapeutic agents such as irinotecan, 
temozolomide, temsirolimus, topotecan, gemcitabine, 
and docetaxel are currently being studied in phase I and 
II trials; retrospective cohort studies show that these 
drugs seem to be active and well tolerated in children 
with recurrent, metastatic, or refractory disease61–70. 
Whether these drugs are of any value for CCSK is not 
currently known.
Follow‑up monitoring
To date, no studies have been performed on the sur-
veillance of patients with CCSK after finishing treat-
ment; thus, follow-up monitoring will be performed 
as conducted in SIOP 2001 (Supplementary Table 1). 
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Cohort studies and case reports have shown that relapses 
in patients with CCSK can occur fairly late (relapses up 
to 8 years after initial diagnosis have been reported); 
thus, vigilance even after 5 years of follow-up duration 
is important21,71. Awareness of relapses in the brain is 
required, and a neurological examination should be part 
of the physical examination during follow-up monitor-
ing owing to the fairly high rate of relapses in the brain 
in patients with CCSK reported in the SIOP–AIEOP 
and NWTS cohort studies20,21. Moreover, brain MRI is 
advised if any suspicion of a cerebral relapse exists and 
if a relapse is detected at another site. The SIOP–AIEOP 
cohort study and NWTS studies also reported bone to be 
a common site of relapse; thus, whole-body MRI, bone 
scan, or FDG–PET scan38 is advised in addition to stand-
ard follow-up examinations if bone relapse is suspected 
and for patients with a relapse detected elsewhere3,21.
The follow-up recommendation includes screening for 
early (within 5 years after diagnosis) and late (>5 years 
after diagnosis or initial treatment) toxicity after intensive 
chemotherapy, including sampling urine (using a dipstick 
test), sampling blood (full blood count, urea, creatinine, 
cystatin C, calcium, phosphate, magnesium, albumin, 
aspartate aminotransferase, alanine aminotransferase, 
bilirubin, and blood gas), echocardiography (after anthra-
cyclines), and audiometry (after carboplatin), on the basis 
of recommendations in national and sometimes interna-
tional guidelines (for example, the recommendations for 
cardiomyopathy surveillance for survivors of childhood 
cancer72) and consensus within the SIOP–RTSG.
Future perspectives
Future studies need to include the effect of highly con-
formal radiotherapy and type of postoperative chemo-
therapeutic treatment on survival and toxicity, preferably 
in international or worldwide randomized controlled 
trials. The limited number of patients in current trial 
settings hampers the design of such studies, especially in 
instances of relapsed disease. Furthermore, development 
of targeted therapies, based on specific molecular aber-
rations of CCSK, is desirable for this group of patients. 
Potential targets for new treatments for CCSK patients 
might be BCOR ITDs (identified in about 80–90% of 
CCSKs), hypermethylation of TCF21 (identified in about 
80–90% of CCSKs) or the YWHAE–NUTM2 fusion gene 
(identified in 5–10% of CCSKs)9,13,14. Finally, immuno-
therapy might be a therapeutic option for patients with 
CCSK in the future73.
Conclusions
To improve survival and reduce short-term and long-
term toxicity of treatment for children diagnosed with 
CCSK, an updated best-available treatment protocol 
(including diagnostic work-up and follow-up sched-
ule) has been developed within the framework of the 
UMBRELLA protocol. The combination of the alky-
lating agents ifosfamide and cyclophosphamide in an 
alternating pattern and the reduction of radiotherapy 
dose from 25.2 to 10.8 Gy (as in COG) to limit serious 
toxicity are hallmarks of this best-available treatment 
regimen, which is based on expert consensus.
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